Persistence of vaccine-induced antibody to measles 26-33 years after vaccination

被引:46
作者
Dine, MS
Hutchins, SS
Thomas, A
Williams, I
Bellini, WJ
Redd, SC
机构
[1] Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA 30333 USA
[2] Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA 30333 USA
[3] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA
关键词
D O I
10.1086/380308
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Because measles-specific antibody titer after vaccination is lower than after natural infection, there is concern that vaccinated persons may gradually lose protection from measles. To examine the persistence of vaccine-induced antibody, participants of a vaccine study in 1971, with documentation of antibody 1 - 7 years after vaccination, were followed up in 1997 - 1999 to determine the presence and titer of measles antibody. Of the 56 participants (77% were 2-dose recipients), all had antibodies detected by the plaque reduction neutralization (PRN) antibody assay an average of 26 - 33 years after the first or second dose of measles vaccine; 92% had a PRN titer considered protective (>1: 120). Baseline hemagglutination inhibition antibody titer in 1971 strongly predicted follow-up PRN antibody titer (P<.001). Persistence of antibody in these primarily 2-dose recipients supports the current elimination strategy to achieve and sustain high population immunity with a 2-dose schedule.
引用
收藏
页码:S123 / S130
页数:8
相关论文
共 31 条
[1]   ROLE OF VIRUS-STRAIN IN CONVENTIONAL AND ENHANCED MEASLES PLAQUE NEUTRALIZATION TEST [J].
ALBRECHT, P ;
HERRMANN, K ;
BURNS, GR .
JOURNAL OF VIROLOGICAL METHODS, 1981, 3 (05) :251-260
[2]   Secondary failure rates of measles vaccines: A metaanalysis of published studies [J].
Anders, JF ;
Jacobson, RM ;
Poland, GA ;
Jacobsen, SJ ;
Wollan, PC .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1996, 15 (01) :62-66
[3]  
[Anonymous], LOGXACT WINDOWS
[4]  
Atkinson W, 2002, EPIDEMIOLOGY PREVENT
[5]   Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination [J].
Bautista-López, N ;
Ward, BJ ;
Mills, E ;
McCormick, D ;
Martel, N ;
Ratnam, S .
VACCINE, 2000, 18 (14) :1393-1401
[6]  
BRUNELL PA, 1990, WHOEPIGEN904
[7]  
Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P557
[8]  
Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1
[9]   MEASLES ANTIBODY - REEVALUATION OF PROTECTIVE TITERS [J].
CHEN, RT ;
MARKOWITZ, LE ;
ALBRECHT, P ;
STEWART, JA ;
MOFENSON, LM ;
PREBLUD, SR ;
ORENSTEIN, WA .
JOURNAL OF INFECTIOUS DISEASES, 1990, 162 (05) :1036-1042
[10]  
DeSerres G, 1996, PEDIATRICS, V97, P232